Research On The Development Strategy Of Hunan IO Biotechnology Co., Ltd.

Xenotransplantation can greatly alleviate the problem of shortage of donor organs,and can create trillions of economic value.In recent years,China and the United States have made many breakthroughs in the field of xenotransplantation.As the only international xenotransplantation company that has obtained the clinical application of xenotransplantation-related technologies,IO Company has a complete upstream and downstream industry chain and independent Intellectual property rights,among which xenotransplantation of islet cell transplantation for diabetes-related technologies is in a leading position in the world.At present,the literature on xenotransplantation at home and abroad is mainly based on scientific research,and there are few researches on related and similar medical technology-based biotechnology companies.Starting from the development strategy of IO Company,this paper focuses on xenotransplantation and other similar restrictive medical treatments.The technology industry and related enterprises conduct comprehensive and pioneering research and analysis,analyze the external situation of the company through relevant tools such as Porter’s Five Forces Model and PEST Model,and conduct SWOT analysis on the enterprise in combination with the internal and external analysis to formulate a suitable enterprise.development implementation strategy.Finally,it is concluded that the company is based on a growth strategy and a parallel strategic model of diversified strategies,which improves the company’s operation level from the strategic level,and at the same time scientifically organizes the system,optimizes the efficiency of capital operation,strengthens the construction of scientific research talent teams,and helps the company in heterogeneity.Transplant this brand-new blue ocean industry to clarify its own positioning and development ideas,and promote the company’s long-term development.This paper studies the development strategy of IO company,which can provide a new material and case for other domestic biotechnology enterprises.This is also the innovation of topic selection in this paper,which can provide useful experience for follow-up research combining strategic management and xenotransplantation.